$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Does afatinib need to be taken on an empty stomach? What should I pay attention to in my diet?
2025-10-19 11:44:20
Check Details
How long does it take to develop drug resistance after taking afatinib, and what are the contraindications?
2025-10-19 11:44:20
Check Details
Can afatinib be purchased in Anhui and how much can it be reimbursed by medical insurance?
2025-10-19 11:44:20
Check Details
The objective response rate of Tagrisso combined with sarvotinib in NSCLC patients with high MET overexpression was 49%_ Kanghule
2025-10-19 11:44:20
Check Details
How long does it take for Osimertinib to take effect and how to judge whether it is effective?
2025-10-19 11:44:20
Check Details
How many tablets of osimertinib should be taken every day and how many years can it be taken?
2025-10-19 11:44:20
Check Details
What should I do if I miss a dose of Osimertinib? What are the dietary taboos?
2025-10-19 11:44:20
Check Details
How much does it cost to pay for Osimertinib through medical insurance?
2025-10-19 11:44:20
Check Details
What should you pay attention to when taking dacomitinib?
2025-10-19 11:44:20
Check Details
Does Dacomitinib affect the liver? How long does it take to stop taking it?
2025-10-19 11:44:20
Check Details
How to take dacomitinib, should it be taken before or after meals?
2025-10-19 11:44:20
Check Details
Can dacomitinib be purchased with medical insurance? How many years can one live taking dacomitinib?
2025-10-19 11:44:20
Check Details
1
2
...
3987
3988
3989
3990
3991
3992
3993
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
2
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
3
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
4
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
5
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
6
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
7
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
8
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
9
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
10
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
11
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
12
Vemurafenib (Zelboraf) Complete Medication Guide